Navigation Links
CNIO and Merck sign license agreement for the development of new cancer drugs
Date:12/18/2013

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development. This global option and license agreement will encourage the development and commercialisation of new compounds in the field of oncology.

With this agreement, the CNIO has granted to Merck exclusive rights to develop and commercialise their new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase. In exchange, Merck will make an initial payment along with other potential income of up to nearly 19 million euros, as well as royalties on net sales.

This agreement is the result of Merck Serono, the biopharmaceutical division of Merck, evaluating a group of ATR inhibitors developed entirely by the CNIO, via its Experimental Therapies Programme and the Genomic Instability Group, led by Joaqun Pastor and scar Fernndez-Capetillo, respectively.

Carmen Vela, Spanish Secretary of State for R&D, who signed the agreement as President of the CNIO Board of Trustees, expressed her satisfaction "at this public-private partnership between a world class research centre and one of the biggest pharmaceutical companies in the world." The Secretary of State underlined the need for "increasing involvement of the private sector in all aspects of Spanish R&D including execution and funding."

"Part of Merck's commitment to oncology includes the focus on strategic agreements that allow us to foster a constant flow of innovations," said Andree Blaukat, Head of Translational Innovation Platform Oncology for Merck Serono. "We are convinced that working with like-minded organizations, like the CNIO, will further strengthen our efforts towards finding the next generation of breakthrough therapies."

"As a research organisation, the CNIO is committed to fostering and promoting innovation. Among other initiatives, the CNIO's Experimental Therapeutics Program carries out early drug discovery projects. The CNIO is delighted to be working with Merck to hopefully translate this research into potential new treatment options for patients with cancer," said Mara Blasco, Director of the CNIO. "It is through collaborations with industry oncology leaders that we can bring CNIO discoveries, such as those made by the group led by Oscar Fernndez-Capetillo, to patients, and contribute new improved products to the battle against cancer."

The agreement encompasses the licensing of two series of ATR inhibitors, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.

ATR kinase has an important role in the response to DNA damage and in facilitating cell survival. Due to the fact that tumour cells accumulate more DNA damage than healthy cells, blocking ATR kinase activity with selective inhibitors appears to be a strategy worth investigating further for specific tumour types.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuits Update: Rottenstein Law Group LLP Comments on Reported $28 Million Merck ‘Jaw Death’ Settlement
2. Merck for Mothers Supports UNICEF’s Efforts to Help Save Lives in South Africa
3. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
4. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
5. Merck and Regenstrief Institute establish evidence-based care collaboration
6. Miami Plastic Surgeon Jon Harrell Advises Patients to Always Use a Licensed Surgeon
7. For The First Time Ever Colorado Issues Recreational Marijuana Sales License
8. Fem Med Formulas Announces an Exclusive License Agreement with NewBridge Pharmaceuticals
9. Wayne State part of team for license on new ways to manage cancer with green tea extracts
10. SeniorQuote Insurance Services Licensed to Support Kansas
11. 265 NY Ambulance and ALS First Responders to Face Stricter License Requirements Regarding Narcotics – MedixSafe Provides Necessary & Reliable Narcotics Security Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... ... top Clinical Data Management Solution Providers list for its expertise in eClinical Solutions. ... domain expertise to serve the technology needs of global clients. DDi provides smarter ...
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... Mystic ... as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. ... a love story, the love of a Buddhist teacher for teaching and helping others. ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. ... , As Winston Churchill said, “Those who don’t learn from history are doomed to repeat ... when they come knocking this year. But that takes time. , Take a close ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... On Thursday, Feb. 11, 2016, surgeons at ... North Austin Medical Center successfully completed the first robotic ... Surgical System with Trumpf Medical,s advanced operating table, ... , M.D., colorectal surgeon at the Texas Institute for ... Motion technology, which seamlessly combines the da Vinci Xi ...
(Date:2/12/2016)... 12, 2016  Eli Lilly and Company (NYSE: LLY ... Alimta® (pemetrexed disodium) vitamin regimen patent would not presently be ... France , Italy and ... product only with dextrose solution.  --> ... Court of Appeal held that Lilly,s patent would be indirectly ...
(Date:2/12/2016)... Ga. , Feb. 12 2016  OMS Supply, ... dental and medical practitioners, announced today the recent launching ... offers visitors a variety of features that enhance the ... oral surgery supplies. --> ... is a fairly new company that started in early ...
Breaking Medicine Technology: